Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN10018 plus taxane and anti-PD-1/PD-L1 antibody in previously treated advanced or metastatic NSCLC
CTR20232566Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ifebemtinib in non-small cell lung cancer (NSCLC), sponsored by InnoCare Pharma. Started Aug 2023; status: active.
02
Drugs
ifebemtinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20232566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232566.